The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
Open accessAbstract
Educational Aims To illustrate the common mechanisms limiting exercise tolerance in patients with chronic lung and heart disease To highlight the impact of lung and heart disease on daily physical activity levels To outline the effects of cardiopulmonary rehabilitation on functional capacity in patients with chronic lung and heart disease To discuss an innovative tele-rehabilitation intervention using information and communications technologies to improve functional capacity in patients with chronic lung and heart disease Summary Shortness of breath associated with cardiorespiratory abnormalities and peripheral muscle discomfort are the major factors that limit exercise capacity in patients with chronic obstructive pulmonary disease (COPD) and those with congestive heart failure (CHF). Both of these symptoms negatively impact on patients’ daily physical activity levels. In turn, poor daily physical activity is commonly associated with increased rates of morbidity and mortality. Cardiopulmonary rehabilitation programmes partially reverse muscle weakness and dysfunction and increase functional capacity in both COPD and CHF. However, benefits gained from participation in cardiopulmonary rehabilitation programmes are regressing soon after the completion of these programmes. Moreover, several barriers limit access and uptake of cardiopulmonary rehabilitation programmes by eligible patients. A potential solution to the underutilisation of cardiopulmonary rehabilitation is the implementation of tele-rehabilitation interventions at home using information and communications technologies. Thus, tele-rehabilitation may be useful to encourage and educate patients with COPD or CHF on how best to maintain and/or further enhance daily physical activity levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taking the proposed mechanism, preclinical and clinical studies into consideration, it is obvious that using radiolabeled SSTR antagonists, especially LM3 and JR11, may provide more successful imaging and PRRT strategies for neuroendocrine tumors, even those with relatively low SSTR expression (130, 137, 141) compared to agonists.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Dasari, A. N., Shen, C., Halperin, D. M., Zhao, B., Zhou, S., Xu, Y., Shih, Y. T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,457
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Öberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M. E., Fave, G. D., Kaltsas, G., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,752
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 616
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Érchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 526
Öberg, K., Knigge, U., Kwekkeboom, D. J., & Perren, A. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds295 · Cited by 523
Aide, N., Lasnon, C., Veit-Haibach, P., Sera, T., Sattler, B., & Boellaard, R. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3740-2 · Cited by 344
Baum, R. P., & Kulkarni, H. (2012) · Theranostics · doi:10.7150/thno.3645 · Cited by 284
Cited by
Sorted by citations
Borgna, F., Haller, S., Rodríguez, J. M. M., Ginj, M., Grundler, P. V., Zeevaart, J. R., Köster, U., Schibli, R., van der Meulen, N. P., & Müller, C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05564-0 · Cited by 123
Yadav, M., Ballal, S., Sahoo, R., & Bal, C. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05632-5 · Cited by 79
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
Lapi, S. E., Scott, P. J. H., Scott, A. M., Windhorst, A. D., Zeglis, B. M., Abdel–Wahab, M., Baum, R. P., Buatti, J. M., Giammarile, F., Kiess, A. P., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00030-5 · Cited by 93
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 86
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
Fortunati, E., Argalia, G., Zanoni, L., Fanti, S., & Ambrosini, V. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00967-z · Cited by 73
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Self-citationThe evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris, P. E., & Zhernosekov, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.941832 · Cited by 65
Carrier systems of radiopharmaceuticals and the application in cancer therapy
Zhang, T., Lei, H., Chen, X., Dou, Z., Yu, B., Su, W., Wang, W., Jin, X., Katsube, T., Wang, B., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01778-3 · Cited by 58
Radiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.
Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers · doi:10.3390/cancers14051172 · Cited by 56
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Wild, D., Grønbæk, H., Navalkissoor, S., Haug, A. R., Nicolas, G. P., Pais, B., Ansquer, C., Beauregard, J., McEwan, A. J. B., Laßmann, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06383-1 · Cited by 54
Peptide Receptor Radionuclide Therapy
Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A., & de Herder, W. W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac574 · Cited by 50
Bidakhvidi, N. A., Goffin, K. E., Dekervel, J., Baete, K., Nackaerts, K., Clément, P. M., Cutsem, E. V., Verslype, C., & Deroose, C. M. (2021) · Cancers · doi:10.3390/cancers14010129 · Cited by 51
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Nock, B. A., Kanellopoulos, P., Joosten, L., Mansi, R., & Μάινα, Θ. (2023) · Pharmaceuticals · doi:10.3390/ph16050674 · Cited by 46
Borgna, F., Barritt, P., Grundler, P. V., Talip, Z., Cohrs, S., Zeevaart, J. R., Köster, U., Schibli, R., van der Meulen, N. P., & Müller, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040536 · Cited by 49
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
Merola, E., & Grana, C. M. (2023) · Cancers · doi:10.3390/cancers15112975 · Cited by 44
di Santo, G., Santo, G., Sviridenko, A., & Virgolini, I. J. (2024) · Theranostics · doi:10.7150/thno.91268 · Cited by 42
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Ambrosini, V., Zanoni, L., Filice, A., Lamberti, G., Argalia, G., Fortunati, E., Campana, D., Versari, A., & Fanti, S. (2022) · Cancers · doi:10.3390/cancers14041055 · Cited by 42
Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
Salvia, A. L., Espinosa-Olarte, P., Martínez, M. C. R., Antón-Pascual, B., & García‐Carbonero, R. (2021) · Cancers · doi:10.3390/cancers13071701 · Cited by 34
Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics
Munekane, M., Fuchigami, T., & Ogawa, K. (2024) · Analytical Sciences · doi:10.1007/s44211-024-00514-w · Cited by 25
Hallqvist, A., Brynjarsdóttir, E., Krantz, T., Sjögren, M., Svensson, J., & Bernhardt, P. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268902 · Cited by 25
Molecular imaging Theranostics of Neuroendocrine Tumors
Fortunati, E., Bonazzi, N., Zanoni, L., Fanti, S., & Ambrosini, V. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.12.007 · Cited by 25
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
Santo, G., di Santo, G., & Virgolini, I. J. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.02.002 · Cited by 23
Kersting, D., Sandach, P., Sraieb, M., Wiesweg, M., Metzenmacher, M., Darwiche, K., Oezkan, F., Bölükbas, S., Stuschke, M., Umutlu, L., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265664 · Cited by 17
Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms
Modica, R., Benevento, E., Liccardi, A., Cannavale, G., Minotta, R., Iasi, G. D., & Colao, A. A. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04140-4 · Cited by 22
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Karimi, A., Bogdani, C., O’Dwyer, E., & Siolas, D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00938-1 · Cited by 23
The Emergence of Somatostatin Antagonist–Based Theranostics: Paving the Road Toward Another Success?
Impériale, A., Jha, A., Meuter, L., Nicolas, G. P., Taïeb, D., & Pacák, K. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265406 · Cited by 19
Kuiper, J., Zoetelief, E., Brabander, T., de Herder, W. W., & Hofland, J. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13469 · Cited by 18
Beykan, S., Eberlein, U., Ansquer, C., Beauregard, J., Durand‐Gasselin, L., Grønbæk, H., Haug, A. R., Hicks, R. J., Lenzo, N. P., Navalkissoor, S., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06682-1 · Cited by 19
Iravani, A., Parihar, A. S., Akhurst, T., & Hicks, R. J. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00465-3 · Cited by 20
Richter, S., Steenblock, C., Fischer, A., Lemm, S., Ziegler, C. G., Bechmann, N., Nölting, S., Pietzsch, J., & Ullrich, M. (2023) · Theranostics · doi:10.7150/thno.87345 · Cited by 16
Perrone, E., Ghai, K., Eismant, A., Andreassen, M., Langer, S. W., Knigge, U., Kjær, A., & Baum, R. P. (2024) · Diagnostics · doi:10.3390/diagnostics14090907 · Cited by 16
Kanellopoulos, P., Nock, B. A., Greifenstein, L., Baum, R. P., Roesch, F., & Μάινα, Θ. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314590 · Cited by 15
Clinical Pharmacology of Radiotheranostics in Oncology
Beek, E. T. T., Burggraaf, J., Teunissen, J. J. M., & Vriens, D. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2598 · Cited by 16
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy
Zhang, S., Zhang, A., Qi, X., Han, Z., Song, L., Zhou, J., Wang, G., Zhu, R., & Li, J. (2025) · Biomimetics · doi:10.3390/biomimetics10060394 · Cited by 17
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
Echavidre, W., Fagret, D., Faraggi, M., Picco, V., & Montemagno, C. (2023) · Cancers · doi:10.3390/cancers15194839 · Cited by 15
Guo, W., Wen, X., Chen, Y., Zhao, T., Liu, J., Tao, Y., Fu, H., Wang, H., Xu, W., Pang, Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.022 · Cited by 14
Liu, M., Ren, C., Zhang, H., Zhang, Y., Huang, Z., Jia, R., Cheng, Y., Bai, C., Xu, Q., Zhu, W., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06790-y · Cited by 14
Boursier, C., Zaragori, T., Imbert, L., & Verger, A. (2024) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.24.03571-4 · Cited by 14
Papadakis, G. Z., Karantanas, A. H., Kostas Marias, A., & Millo, C. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109932 · Cited by 14
Viswanathan, R., Ballal, S., Yadav, M. P., Roesch, F., Sheokand, P., Satapathy, S., Tripathi, M., Agarwal, S., Moon, E. S., & Bal, C. (2024) · Pharmaceuticals · doi:10.3390/ph17030275 · Cited by 13
Radiometal-theranostics: the first 20 years*
Roesch, F., & Martin, M. (2022) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-022-08624-3 · Cited by 15
Grey, N., Silosky, M. S., Lieu, C. H., & Chin, B. B. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i17.1768 · Cited by 12
Nguyen, N. T., Min, Y., Rivière, J., van der Garde, M., Ghosh, S. C., Bartos, L. M., Brendel, M., Bassermann, F. C., Azhdarinia, A., Weber, W., et al. (2025) · Theranostics · doi:10.7150/thno.113354 · Cited by 14
Nock, B. A., Kanellopoulos, P., Moon, E. S., Rouchota, M. G., Loudos, G. K., Ballal, S., Yadav, M. P., Bal, C. S., Mishra, P. K., Sheokand, P., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030776 · Cited by 11
Novel bio-carriers for radionuclide delivery in cancer radiotherapy
Wang, L., He, Q., Man, J., Gao, Y., Zhou, G., Si, H., Yang, K., Hu, L. T., & Pei, P. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216557 · Cited by 10
Perrone, E., Calcagni, M. L., Leccisotti, L., Moretti, R., Ghai, K., Eismant, A., Parkar, T., Greifenstein, L., & Baum, R. P. (2025) · Cancers · doi:10.3390/cancers17183070 · Cited by 8
Virgolini, I. J., di Santo, G., & Santo, G. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07750-w · Cited by 8
Bodei, L., Gnanasegaran, G., Giammarile, F., Pavel, M., Ambrosini, V., Baum, R. P., Hörsch, D., Howe, J. R., Cremonesi, M., El-Haddad, G., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100017 · Cited by 8
New horizon of radiopharmaceuticals in management of neuroendocrine tumors
Haq, A., Rayamajhi, S. J., Ponisio, M. R., & Prasad, V. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101797 · Cited by 8
Shanmugiah, J., & Kim, J. S. (2026) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-026-00988-8 · Cited by 8
Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside
Mansi, R., & Fani, M. (2021) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2021.500 · Cited by 7
Yamaguchi, N., Wei, J., & Isomoto, H. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02241-z · Cited by 6
Recent Trends in Radiopharmaceuticals: Focused on Drug Delivery to the Targeted Tissues
Ito, T., Hachisuka, A., Ishii‐Watabe, A., Saito, Y., Demizu, Y., & Misawa, T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00407 · Cited by 5
Wang, Q., Librizzi, D., Bagheri, S., Ebrahimifard, A., Shamami, A. H., Rinke, A., Eilsberger, F., Luster, M., & Yousefi, B. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178539 · Cited by 5
Cai, J., Zhu, Y., Zhu, X., Hosmane, N. S., Ding, Q., & Zhu, Y. Z. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217448 · Cited by 5
Fricke, J. G., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., Geistlich, S., Schmid, D. E., Borgna, F., Fani, M., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270654 · Cited by 5
Speicher, T., Burgard, C., Bastian, M. B., Rosar, F., Bartholomä, M. D., Maus, S., & Ezziddin, S. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005439 · Cited by 5
Hindié, E., Baudin, É., Hicks, R. J., & Taïeb, D. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264422 · Cited by 5
New approaches in nuclear medicine theranostics
Enke, J. S., Fenzl, L., Lapa, C., & Viering, O. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf143 · Cited by 4
Smith, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1572118 · Cited by 4
Baberwal, P., & Basu, S. K. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2589524 · Cited by 4
Resch, S., & Delker, A. (2026) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2026.03.011 · Cited by 4
Ordas, L., Foster, S., Pham, P., Ollendorff, A. S., Gnanasekar, V., Toulany, M., & Sodji, Q. H. (2026) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkag056 · Cited by 4
Shekhda, K. M., & Navalkissoor, S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.07.002 · Cited by 4
Radiopharmaceuticals in Nasopharyngeal Cancer
Xu, X., Tang, X., Wu, W.-Y., Liu, M., & Zeng, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108281 · Cited by 4
Molecular Imaging in neuroendocrine neoplasias
Christ, E., Wild, D., & Refardt, J. C. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104115 · Cited by 4
Preliminary experiments to produce lutetium-177 in the TRR-1/M1 Thai research reactor
Ragchana, P., Saengkaew, P., Wetchagarun, S., Tiyapun, K., Dangprasert, M., & Khamwan, K. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.111708 · Cited by 3
Liu, M., Zhang, Y., Yan, X., Zhang, H., Ren, C., Huang, Z., Cheng, Y., Xu, Q., Li, Y., Jia, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07484-9 · Cited by 3
Deroose, C. M., Ambrosini, V., Hofland, J., Kaltsas, G., Kjær, A., Lamarca, Á., Sowa-Staszczak, A., Janson, E. T., & Fazio, N. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70220 · Cited by 3
Small Bowel Neuroendocrine Neoplasms—A Review
Vulasala, S. S., Virarkar, M., Gopireddy, D. R., Waters, R., Alkhasawneh, A., Awad, Z. T., Maxwell, J. E., Ramani, N. S., Kumar, S. P., Onteddu, N. K. R., et al. (2023) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001541 · Cited by 3
Xing, H., Zhu, W., Cheng, Y., Yang, Q., Jia, R., Zhao, H., Bai, C., Huo, L., & Wu, W. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000101 · Cited by 3
Zhu, W., Liu, M., & Huo, L. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000122 · Cited by 3
Theranostic Imaging and Radiopharmaceutical Therapy
Duan, H., & Iagaru, A. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_22 · Cited by 2
Mansi, R., Bertarelli, N., Pozzo, L. D., Zanger, S., Bernabeu, T. B., Maëcke, H. R., & Fani, M. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00363-6 · Cited by 2
Greifenstein, L., Martin, M., Stephan, S., Eismant, A., Kramer, C. S., Landvogt, C., Mueller, C., Rösch, F., & Baum, R. P. (2026) · Pharmaceuticals · doi:10.3390/ph19010172 · Cited by 2
Practical Aspects of 161Tb Production
Skálová, M., Janská, T., Štíbr, M., Vlk, M., Šoltés, J., Vins, M., Hassfjell, S. P., Muller, J., & Kozempel, J. (2026) · Pharmaceuticals · doi:10.3390/ph19040619 · Cited by 2
Baum, R. P., Zhao, T., Jakobsson, V., Greifenstein, L., Eismant, A., Ghai, K., Mishra, A., Klega, A., Landvogt, C., Mueller, C., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271129 · Cited by 2
Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies
Grewal, U. S., Shaheen, S., Zhen, D. B., Mittra, E., Halfdanarson, T. R., Singh, S., & Chan, J. A. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-518934 · Cited by 2
State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms
Ambrosini, V., Fortunati, E., Fanti, S., Ursprung, S., Asmundo, L., O’Shea, A., Kako, B., Lee, S. I., Furtado, F., Blake, M. A., et al. (2024) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001594 · Cited by 2
Wild, D., & Fani, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_16 · Cited by 1
Speicher, T., Burgard, C., Rosar, F., Bastian, M. B., Bartholomä, M. D., Maus, S., & Ezziddin, S. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005938 · Cited by 1
Radionuclides for imaging and therapy in oncology
Velikyan, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22253-5.00026-1 · Cited by 1
Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives
Ai, D., Li, J., Shi, J., Sang, S., Zhang, B., Ge, S., & Deng, S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114865 · Cited by 1
Bogdani, C., Karimi, A., Li, R., Atkinson, E. C., Oberstein, P. E., & Siolas, D. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00833 · Cited by 1
Clinical Applications of Theranostics
Kuten, J., Bodei, L., & Lewis, J. S. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-21415-7_17 · Cited by 1
Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation
Liu, J., Zuo, X., Yang, X., Wang, X., Gan, L., & Xue, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02695-6 · Cited by 1
Update on PET Imaging of Neuroendocrine Neoplasms
Singh, C., Gupta, M., Panda, A., Prakash, A., Mhlanga, J. C., Catalano, O. A., & Virarkar, M. (2026) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2026.06.006 · Cited by 1
Theranostics and Molecular-targeted Endo-radiotherapy: The Current Landscape and Future Directions
Nazar, A. K., & Basu, S. K. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006120 · Cited by 1
So, E., Morizane, C., & Okusaka, T. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261471127 · Cited by 1
Bakr, H., Al-Awar, A., Spetz, J. K. E., & Forssell-Aronsson, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198709 · Cited by 1
May the Nuclear Medicine be with you! Neuroendocrine tumours and the return of nuclear medicine
Ekmekçioğlu, Ö., Hughes, S., Fendler, W. P., Verzijlbergen, F. J., Kong, G., & Hofman, M. S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06877-6 · Cited by 1
Ballal, S., Sheokand, P., Yadav, M. P., Roesch, F., Viswanathan, R., Satapathy, S., Tripathi, M., Moon, E. S., Mishra, P., Rastogi, S., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005649 · Cited by 1
Perrone, E., Ghai, K., Eismant, A., & Baum, R. P. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005782 · Cited by 1
Peptidradiorezeptor-Therapie (PRRT)
Buck, A. K., Lapa, C., Weich, A., Higuchi, T., Hasenauer, N., Hänscheid, H., & Werner, R. A. (2021) · Der Nuklearmediziner · doi:10.1055/a-1556-8323
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_303-1
Theranostics in Neuroendocrine Tumors
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_21
Greifenstein, L., Kramer, C. S., Grus, T., Rösch, F., Klega, A., Landvogt, C., Müller, C., Marx, S., & Baum, R. P. (2023) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0043-1766141
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapy
Stasio, G. D. D., Farulla, L. S. A., Botta, F., Gilardi, L., & Grana, C. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_14
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., Iasi, G. D., & Colao, A. A. L. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_265
Metadata
- Authors
- Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H.
- Affiliations
- Zentralklinik Bad Berka (DE)
- National University of Singapore (SG)
- University Medical Center Freiburg (DE)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2021-03-05
- Volume
- 62
- Issue
- 11
- Pages
- 1571-1581
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC8612334
- OpenAlex
- W3133553083
- Cited by
- 127
- References
- 38
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 18 · 2023: 19 · 2022: 15 · 2021: 8
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- somatostatin receptor antagonists, peptide receptor radionuclide therapy, metastatic neuroendocrine tumors, dosimetry, treatment safety, treatment efficacy
- MeSH terms
- Adult, Aged, Female, Humans, Lutetium, Male, Middle Aged, Neoplasm Metastasis, Organometallic Compounds, Radioisotopes, Radiometry, Safety, Octreotide, Treatment Outcome, Receptors, Somatostatin, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
